Results 61 to 70 of about 5,351 (123)

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics

Pathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou, Panagiotis Stathopoulos, Christos Vrysis, Iva D. Tzvetanova, Matthew E. Falagas   +4 more
doaj   +1 more source

Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies

Microorganisms
This review provides an overview of recent research and advancements in infection prevention and the treatment of drug-resistant bacterial diseases.
Majid Eslami, Amirabbas Safaripour, Seyedeh Zahra Banihashemian, Sahar Nikjoo Niaragh, Mohammad Amin Hemmati, Arefeh Shojaeian, Setayesh Fakhariyan, Atiye Rabbani, Valentyn Oksenych   +8 more
doaj   +1 more source

Case Report: Successful salvage therapy with sulbactam-durlobactam combined with meropenem for carbapenem-resistant Acinetobacter baumannii bloodstream infection in a child after failure of allogeneic hematopoietic stem cell transplantation

Frontiers in Pediatrics
Bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii (CRAB) constitute a serious complication in patients undergoing hematopoietic stem cell transplantation (HSCT), with pediatric patients facing particularly formidable ...
Qian Zhang, Chunjing Wang, Zhiheng Ding, Jiayi Lyu, Yu Zhang, Fangyuan Lai, Ruihao Zheng, Sixi Liu   +7 more
doaj   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

In vitro interactions of sulbactam/durlobactam in combination with meropenem, ceftazidime/avibactam, piperacillin/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates

: We evaluated in vitro activity of sulbactam/durlobactam in combination with different antimicrobials against Carbapenem-Resistant Acinetobacter baumannii (CRAB) clinical isolates with different susceptibility profiles, including sulbactam/durlobactam ...
Zocche, Giulia, Lewis, Russell E, Tascini, Carlo, Gaibani, Paolo, Bianco, Gabriele   +4 more
core   +1 more source

Case report: Successful treatment of OXA-23 neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy

Meningitis caused by species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality. Carbapenem-resistant is particularly difficult to treat, considering the limited selection and tolerability of
Rawlings, Stephen A, Snowdin, Jacob W, Madaio, Michael P, Mercuro, Nicholas J   +3 more
core   +1 more source

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations

Microbiology Spectrum
Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. represent major threats and have few approved therapeutic options. Non-‍fermenting Gram-negative isolates were collected from hospitalized inpatients from 49 sites in 6 European countries
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, John D. Perry, Mathias W. Pletz, Stefania Stefani, Ian Morrissey, Christopher Longshaw   +7 more
doaj   +1 more source

Sulbactam-containing β-lactamase inhibitor combinations [PDF]

, 2008
Sulbactam irreversibly inhibits the hydrolytic activity of β-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against β-lactamase-producing
Sierra Valverde, Álvaro Javier, Akova, M.   +1 more
core   +1 more source

The epidemiological and molecular characteristics and sulbactam-durlobactam susceptibility of carbapenem-resistant Acinetobacter baumannii in a Chinese teaching hospital

Journal of Global Antimicrobial Resistance
: Objectives: This study aimed to investigate sulbactam-durlobactam (SUL-DUR) susceptibility and molecular features of carbapenem-resistant Acinetobacter baumannii (CRAB) isolates from a Shenzhen teaching hospital. Methods: A retrospective study on CRAB
Hanlian Huang, Qiaomin Zhang, Shaobo Li, Xiaoyan Dai, Zhongbiao Chen, Guili Zhang, Wen Ma, Hongwei Shen   +7 more
doaj   +1 more source

Resistance to sulbactam/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates

Objectives: This study evaluated the in vitro activity of sulbactam/durlobactam and comparators against carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream isolates from Italy and investigated genomic mechanisms underlying resistance. Methods:
Boattini, Matteo, Biffignandi, Gherard Batisti, Vumbaca, Michela, Comini, Sara, Costa, Cristina, Gaibani, Paolo, Bianco, Gabriele   +6 more
core   +1 more source